Rob Hooft van Huijsduijnen
Overview
Explore the profile of Rob Hooft van Huijsduijnen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
2261
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Samby K, Besson D, Dutta A, Patra B, Doy A, Glossop P, et al.
ACS Infect Dis
. 2022 Mar;
8(4):713-720.
PMID: 35286809
The current Covid-19 pandemic has underlined the need for a more coordinated and forward-looking investment in the search for new medicines targeting emerging health care threats. Repositioning currently approved drugs...
2.
Hooft van Huijsduijnen R, Kojima S, Carter D, Okabe H, Sato A, Akahata W, et al.
PLoS Negl Trop Dis
. 2020 Jan;
14(1):e0007860.
PMID: 31999695
In the past two decades there has been a significant expansion in the number of new therapeutic monoclonal antibodies (mAbs) that are approved by regulators. The discovery of these new...
3.
Hooft van Huijsduijnen R, Wells T, Tanner M, Wittlin S
Malar J
. 2019 Mar;
18(1):94.
PMID: 30902051
Over the last two decades there has been a renaissance in the pipeline of new drugs targeting malaria, with the launch of new products that help save the lives of...
4.
Burrows J, Slater H, Macintyre F, Rees S, Thomas A, Okumu F, et al.
Malar J
. 2018 Dec;
17(1):462.
PMID: 30526594
Reaching the overall goal of eliminating malaria requires halting disease transmission. One approach to blocking transmission is to prevent passage of the parasite to a mosquito, by preventing formation or...
5.
Macintyre F, Ramachandruni H, Burrows J, Holm R, Thomas A, Mohrle J, et al.
Malar J
. 2018 Nov;
17(1):402.
PMID: 30384848
Over the last 15 years, the majority of malaria drug discovery and development efforts have focused on new molecules and regimens to treat patients with uncomplicated or severe disease. In...
6.
Llanos-Cuentas A, Casapia M, Chuquiyauri R, Hinojosa J, Kerr N, Rosario M, et al.
Lancet Infect Dis
. 2018 Jun;
18(8):874-883.
PMID: 29909069
Background: DSM265 is a novel, long-duration inhibitor of plasmodium dihydroorotate dehydrogenase (DHODH) with excellent selectivity over human DHODH and activity against blood and liver stages of Plasmodium falciparum. This study...
7.
Hooft van Huijsduijnen R, Wells T
Curr Opin Pharmacol
. 2018 Jun;
42:1-6.
PMID: 29860174
Over the past decade, new high-throughput phenotypic assays with malaria parasites have been developed, and these were used to screen millions of compounds. This effort, as well as improving older...
8.
Phillips M, Burrows J, Manyando C, Hooft van Huijsduijnen R, Van Voorhis W, Wells T
Nat Rev Dis Primers
. 2017 Aug;
3:17050.
PMID: 28770814
Malaria is caused in humans by five species of single-celled eukaryotic Plasmodium parasites (mainly Plasmodium falciparum and Plasmodium vivax) that are transmitted by the bite of Anopheles spp. mosquitoes. Malaria...
9.
Alirol E, Wi T, Bala M, Bazzo M, Chen X, Deal C, et al.
PLoS Med
. 2017 Jul;
14(7):e1002366.
PMID: 28746372
Emilie Alirol and colleagues discuss the development of new treatments for gonorrhea.
10.
Burrows J, Duparc S, Gutteridge W, Hooft van Huijsduijnen R, Kaszubska W, Macintyre F, et al.
Malar J
. 2017 Apr;
16(1):151.
PMID: 28420400
No abstract available.